Objective-To explore the role of LAL (lysosomal acid lipase) in macrophage cholesterol efflux and whole-body reverse cholesterol transport. Approach and Results-Immortalized peritoneal macrophages from lal −/− mice showed reduced expression of ABCA1 (ATPbinding cassette transporter A1) and ABCG1 (ATP-binding cassette transporter G1), reduced production of the regulatory oxysterol 27-hydroxycholesterol, and impaired suppression of cholesterol synthesis on exposure to acetylated low-density lipoprotein when compared with lal +/+ macrophages. LAL-deficient mice also showed reduced hepatic ABCG5 (ATP-binding cassette transporter G5) and ABCG8 (ATP-binding cassette transporter G8) expression compared with lal +/+ mice. LAL-deficient macrophages loaded with [ from macrophages and whole-body reverse cholesterol transport (RCT). Different from our results using LAL-deficient fibroblasts, a recent study reported macrophages generated from human pluripotent stem cells and lacking LIPA expression had a similar upregulation of ABCA1 in response to acetylated LDL (acLDL) loading as cells expressing LIPA.
R etention and uptake of low-density lipoprotein (LDL) and other apolipoprotein B-containing lipoproteins by cells in the artery wall is the key driver of atherosclerosis development. 1 Lipoprotein cholesterol ingested by artery wall cells, including macrophages, is primarily in the ester form, which must be hydrolyzed in and released from lysosomes to allow eventual removal of the excess cholesterol from cells. The sole lysosomal enzyme known to perform this function is LAL (lysosomal acid lipase), encoded by the gene LIPA. 2 The critical importance of LAL is indicated by the lethality of complete LAL deficiency (Wolman disease), and by the liver disease, lipoprotein abnormalities and premature atherosclerosis seen individuals with subtotal LAL deficiency (cholesteryl ester storage disease). 3, 4 Modification of LAL by mannose-6-phosphate allows the uptake of exogenous LAL by cells and targeting to lysosomes, 5 where it has been shown to correct the consequences of LAL deficiency at the cellular level. 6, 7 rhLAL (recombinant human LAL protein) delivered intravenously to humans is lifesaving in Wolman Disease 8 and has been shown to rapidly correct the liver and lipoprotein abnormalities in individuals with cholesteryl ester storage disease, 9 indicating its efficient uptake in tissues from the circulation.
We previously reported that LAL deficiency in human skin fibroblasts leads to impaired upregulation of ABCA1 (ATPbinding cassette transporter A1) and ABCG1 (ATP-binding cassette transporter G1)-2 mediators of cholesterol efflux and high-density lipoprotein (HDL) formation-after cholesterol loading and correction of these defects after delivery of exogenous LAL to the cells. 7 Although there is some suggestion of benefit of delivery of exogenous LAL in reducing atherosclerosis, 10 the mechanism of this is not understood, including the role of LAL in promoting cholesterol efflux from macrophages and whole-body reverse cholesterol transport (RCT). Different from our results using LAL-deficient fibroblasts, a recent study reported macrophages generated from human pluripotent stem cells and lacking LIPA expression had a similar upregulation of ABCA1 in response to acetylated LDL (acLDL) loading as cells expressing LIPA. 11 In the current studies, we have utilized immortalized peritoneal macrophages from lal +/+ and lal −/− mice to study the effect of LAL deficiency and replacement on cholesterol metabolism in cultured macrophages and the role of LAL in promoting whole-body RCT from lipoprotein cholesteryl esters (CEs) in macrophages to the plasma, liver, and feces of lal +/+ and lal −/− mice. Our results indicate a major role for LAL in the regulation of macrophage and whole-body RCT and the ability of supplemental LAL to correct these defects in LAL deficiency.
Materials and Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement or available from the corresponding author on request. Materials and additional Methods are available in the online-only Data Supplement.
Preparation of 3 H-Cholesteryl-Oleate-Labeled acLDL and Isolation of apoA-I From Plasma
LDL was isolated from pooled plasma from fasting, healthy donors by density gradient ultracentrifugation. 12 Radiolabeling of LDL with 3H-cholesteryl oleate was performed as described previously, 13 and then acetylated according to the methods in the study by Basu et al. 14 Briefly, an equal volume of 3 H-cholesteryl-oleate-labeled LDL in saline solution (typically 4-5 mL) was mixed with an equal volume of a saturated sodium acetate solution, and 1.5 µl acetic anhydride per mg acLDL protein was added in 1-µl aliquots for 1 hour, while stirring on ice and then dialyzed extensively in a saline-EDTA solution. apoA-I (apolipoprotein A-I) was purified from human plasma using Q-Sepharose Fast Flow chromatography as described.
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LAL-Deficient Mice
LAL null mice (lal −/− ) were generated on a CF-1/129Sv genetic background as described previously. 16 
Cell Culture
Mouse wild-type (lal +/+ ) or LAL knockout mice (lal −/− ) immortalized peritoneal macrophages were isolated by peritoneal lavage and engineered to have temperature-sensitive expression of SV40 large T-antigen under an IFN-γ (interferon gamma)-inducible promoter, using methods described in the study by Castoreno et al.
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Cholesterol Efflux Assay
Radiolabeled acLDL loading of macrophages and efflux to apoA-I were performed as described in the online-only Data Supplement. Cellular lipids were separated by thin-layer chromatography. Unesterified cholesterol (UC) and CE spots were located on plates using unlabeled carrier lipids stained with iodine gas, and radioactivity was quantified by liquid scintillation counting 18 as described previously. 7, 19 Medium UC and cell UC and CE were calculated as the percentage of total 3H-sterol (cell+medium).
Mevalonolactone Incorporation Assay
Using radiolabeled mevalonolactone, radioactivity in newly synthesized cholesterol was quantified by liquid scintillation counting as described previously 20 and normalized to cell proteins.
Measurement of 27-Hydroxycholesterol Production
The mass of 27-hydroxycholesterol (ng) was determined by HPLC (high-performance liquid chromatography) tandem mass spectrometry by modification of a previously described method.
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Macrophage RCT
Methods to measure macrophage to feces RCT were adapted from previous publications [22] [23] [24] as described in the online-only Data Supplement.
Statistical Analysis
Results were analyzed using GraphPad Prism, version 5.0, for statistical significance between treatment groups. The normality of data for figures was determined by performing a D'Agostino and Pearson omnibus normality test (α=0.05) and by visual inspection of normality using Q-Q plots. Normally distributed data were analyzed using parametric tests, either a 1-way ANOVA with Bonferroni post hoc comparisons or a Student t test, as indicated in the figure legends. Data not normally distributed were analyzed using nonparametric tests, either a Kruskal-Wallis test with Dunn comparisons or a Mann-Whitney U test, as indicated in the figure legends. A P value <0.05 was considered significant.
Results
ABCA1 Expression and Cholesterol Efflux Are Impaired in Macrophages Lacking LAL and Corrected by Addition of Exogenous LAL
Macrophages are a primary site of cholesterol deposition in atherosclerotic plaque, and the level of ABCA1 expression is the rate-limiting determinant of removal of excess cholesterol by apoA-I from these cells. 25 To determine the role of LAL in regulating ABCA1 expression and other determinants of macrophage cholesterol efflux, we used immortalized peritoneal macrophages obtained from wild-type (lal +/+ ) and LAL-deficient (lal −/− ) mice. In contrast to the robust increase in ABCA1 expression in response to incubating lal +/+ macrophages with acLDL, lal −/− macrophages exhibited significantly reduced basal and acLDL-stimulated increase in ABCA1 mRNA and protein levels ( Figure 1A and 1B hours resulted in a significant increase in ABCA1 mRNA and protein levels in lal −/− macrophages ( Figure 1A through 1C ). This is consistent with the role of LAL in hydrolyzing lipoprotein CEs and the subsequent release of this cholesterol from lysosomes driving ABCA1 expression. 7 In contrast, addition of supplemental rhLAL to lal +/+ macrophages stimulated no further increase in ABCA1 mRNA ( Figure 1A ) or protein ( Figure 1C ).
Cholesterol efflux from macrophages is also mediated by ABCG1, apoE (apolipoprotein E), and SR-BI (scavenger ) mouse immortalized peritoneal macrophage cell lines were grown to confluence and supplemented without (−) or with (+) 50 µg/ mL acetylated low-density lipoprotein (acLDL) for 24 h. Some dishes of lal −/− cells were also treated with 5, 10, or 20 µg/mL of rhLAL 1 h before and during acLDL loading. A, ABCA1 mRNA expression in the absence or presence of acLDL and 20 µg/mL rhLAL was measured by quantitative real-time PCR (polymerase chain reaction), corrected for the housekeeping gene m-cyclophilin and normalized relative to the lal +/+ control. B, ABCA1 protein levels were resolved by SDS-PAGE, detected by Western blotting using polyclonal antibodies against ABCA1 or PDI (protein disulfide isomerase) loading control and normalized relative to the lal +/+ control. Error bars are shown as SEM from (A) 6 or (C) 8 experiments using ±20 µg/mL rhLAL (*P<0.05, Kruskal-Wallis test with Dunn comparisons, significantly different from lal +/+ with no acLDL, unless otherwise indicated).
receptor class B type 1). Similar to ABCA1, lal −/− macrophages showed significantly lower ABCG1 mRNA than lal +/+ macrophages in the basal state and after acLDL loading ( Figure 2 ). ApoE mRNA showed a nonsignificant trend to higher levels in lal −/− compared with lal +/+ macrophages in both the basal and acLDL-loaded conditions. No significant differences were seen in SR-BI mRNA in the basal condition or after acLDL loading of lal +/+ and lal −/− macrophages. The role of LAL in promoting removal of excess cholesterol from macrophage foam cells was then determined after cholesterol loading with acLDL and incubation with apoA-I to determine ABCA1-dependent cholesterol efflux. Cells of both genotypes were loaded with 3H-cholesteryl oleatelabeled acLDL for 24 hours, and 3H-UC counts in the medium and 3H-CE and 3H-UC counts in cells were quantified after a 24-hour incubation with or without 10 μg/mL apoA-I ( Figure 3 ). Elevated levels of 26, 27 and which is ABCA1 dependent. 28 Addition of apoA-I to medium significantly further increased efflux in lal +/+ macrophages ( Figure 3A ). Efflux to medium alone was reduced to almost half of wild-type levels in lal −/− macrophages ( Figure 3A ). This is consistent with both the reduced cellular pool of 3 H-UC available for efflux ( Figure 3C ) and reduced ABCA1 (Figure 1 ), both reducing the efflux potential of macrophage-secreted apoE ( Figure II in the online-only Data Supplement). For the same reasons, addition of apoA-I did not significantly increase efflux from lal −/− macrophages ( Figure 3A ). Treatment of lal −/− cells with 10 µg/ mL rhLAL significantly increased cholesterol efflux to apoA-I ( Figure 3A) , consistent with the upregulation of ABCA1 in these cells ( Figure 1 ) and reduced availability of UC for efflux. As expected, lal −/− macrophages showed increased cellular 3H-CE and reduced 3H-UC when compared with lal +/+ macrophages. CE hydrolysis in lal −/− macrophages was corrected with a consequent increase in 3 H-UC after addition of rhLAL ( Figure 3B and 3C). This result is consistent with the ability of exogenous LAL to be taken up, delivered to lysosomes, and mediate neutral lipid hydrolysis in both cultured cells 6, 7 and in vivo. 
Dysregulation of Postlysosomal Cholesterol Metabolism in Lal −/− Macrophages and Correction by Exogenous LAL
Reduced release of lipoprotein-derived cholesterol from lysosomes in LAL-deficient human fibroblasts has previously been shown to impair downstream regulatory events, including suppression of cholesterol synthesis 29 and upregulation of ABCA1 expression. 7 To further investigate the importance of LAL in regulating cholesterol homeostasis in macrophages, we measured production of 27-hydroxycholesterola key endogenous LXR (liver X receptor) agonist oxysterol upregulating ABCA1 expression in the artery wall 30 -and new cholesterol synthesis from the cholesterol precursor mevalonate, before and after addition of acLDL. Formation Figure 4A ). Addition of rhLAL resulted in a similar fold increase in 27-hydroxycholesterol synthesis in lal −/− as seen in lal +/+ macrophages treated with acLDL. Incubation with acLDL for 24 hours resulted in a modest but significant reduction of new cholesterol synthesis from mevalonate in lal +/+ macrophages ( Figure 4B ). Lal −/− macrophages showed significantly higher new cholesterol synthesis in the basal condition and after loading with acLDL compared with lal +/+ macrophages. Addition of rhLAL to lal −/− macrophages reduced their synthesis of new cholesterol down to a level similar to lal +/+ cells ( Figure 4B ). These 2 results confirm the dysregulation of cholesterol homeostasis in lal −/− macrophages and provide a likely reason for impaired upregulation of ABCA1 after addition of acLDL, failure to increase formation of the key LXR agonist 27-hydroxycholesterol in the presence of LAL deficiency. Supplementation of exogenous rhLAL corrects these pathways as reflected in the increased ABCA1 expression, correction of cholesterol efflux to apoA-I by lal −/− macrophages, and suppression of de novo cholesterol synthesis.
Expression of Genes Affecting Hepatic and Fecal Cholesterol Secretion and Efflux in Lal-Deficient Mice
To further investigate the role of LAL in regulating genes involved in RCT, mRNA levels for ABCA1, ABCG5, ABCG8, and SRBI were determined in livers isolated from lal +/+ and lal −/− mice. Hepatic ABCA1 and SR-BI mRNA levels were not significantly different between genotypes ( Figure 5A ), consistent with lack of LXR responsiveness of these genes in mouse liver. 31 Hepatocyte LXR-dependent genes ABCG5 (ATP-binding cassette transporter G5) and ABCG8 (ATPbinding cassette transporter G8; ABCG5/G8) 32 showed significantly lower mRNA levels in lal −/− compared with lal +/+ mouse liver ( Figure 5A ), as reported previously 33 ; these results were confirmed at the protein level ( Figure 5B ). No sex differences were seen in expression of these genes in both lal +/+ or lal −/− mice, consistent with previous studies showing lack of major differences between male and female lal −/− mice. 33, 34 Despite normal hepatic mRNA levels, levels of ABCA1 protein were lower in the livers of lal −/− mice ( Figure 5B ); ABCA1 protein was also lower in the spleen, kidney, and skin fibroblasts of lal −/− compared with lal +/+ mice ( Figure III in the online-only Data Supplement). Intestinal ABCA1 protein levels were not found to be reduced in lal −/− compared with lal +/+ mice (data not shown); similar results have been found previously, depending on the segment of intestine assessed (S. Turley, personal communication). Although lal −/− mouse liver Cyp7A1 mRNA was found to be reduced, we found no reduction in Cyp7A1 protein levels in lal −/− when compared with livers of lal +/+ mice (data not shown). This finding is consistent with equivalent rates of bile acid secretion in lal +/+ and lal −/− mice reported previously.
33 Figure 3 . Rescue of impaired apoA-I (apolipoprotein A-I)-dependent cholesterol efflux in lal −/− macrophages by treatment with rhLAL (recombinant human lysosomal acid lipase protein). Immortalized mouse peritoneal macrophages were grown to confluence and loaded with 50 µg/ mL 3 H-CE-labeled acetylated low-density lipoprotein (acLDL) for 24 h and then washed and incubated in the presence (+ApoA-I) or absence (−ApoA-I) of 10 µg/mL purified apoA-I for 24 h. Where indicated, 20 µg/ mL rhLAL was added 1 h before and during acLDL loading. A, Medium was removed, and 3H-cholesterol was quantified by LSC. B and C, From cells that were not incubated with apoA-I, cellular lipids were extracted, cellular 3H-cholesteryl esters and 3H-unesterified cholesterol were separated by thin-layer chromatography and counted by LSC. Figure 6A ). Despite this, no significant difference in liver 3H-sterol was observed between the lal +/+ into +/+ versus lal −/− into −/− mice, when expressed as either percentage of total counts per minute (CPM) injected ( Figure 6B ) or cpm/mg liver protein (not shown). This likely reflects accumulation of 3 H-cholesterol that does reach the liver in lal −/− mice because of decreased expression of ABCG5 and ABCG8 ( Figure 5 ) and, therefore, reduced excretion from the liver into bile in these mice. Consistent with this, for 48 hours, lal −/− mice injected with lal −/− macrophages showed reduced appearance of 3 H-cholesterol in feces (1.55±0.35% of total CPM injected) compared with the lal +/+ macrophage into lal +/+ mouse group (5.38±0.92% of injected label; Figure 6C ). To mimic the therapeutic condition of uptake of supplemental LAL by LAL-deficient macrophages, 3H-CE-labeled lal −/− macrophages were injected into lal +/+ mice. This resulted in significantly increased appearance of 3 H-sterol in plasma (1.36±0.08%) and feces (2.60±0.46%; n=19 mice) at 48 hours . Impaired regulation of oxysterol production and cholesterol synthesis in lal −/− macrophages and correction with rhLAL (recombinant human lysosomal acid lipase protein). A, Immortalized mouse peritoneal macrophages were grown to confluence and treated with ±50 µg/mL acetylated low-density lipoprotein (acLDL) for 24 h. In addition, lal −/− macrophages were also pretreated with 10 µg/mL rhLAL 1 h before and during acLDL loading. Cell monolayers were then washed and equilibrated for an additional 24 h in medium alone. After lipid extraction, the mass of 27-hydroxycholesterol was determined by HPLC tandem mass spectrometry and normalized to cell proteins. Results are indicated as fold change relative to nonlipid loaded controls. B, Immortalized mouse peritoneal macrophages were grown to confluence and loaded with 0.5 µCi/mL 
Discussion
LAL is the sole lysosomal enzyme mediating hydrolysis of CEs derived from endocytosed lipoproteins and also stored CEs delivered to lysosomes by lipophagy. In the current studies, we provide evidence for a critical role of LAL in driving expression of ABCA1 in macrophages and multiple tissues, cholesterol efflux from cells, and excretion of cholesterol from the liver into the feces. In addition, we show that reduced cholesterol flux from lysosomes because of LAL deficiency results in impaired oxysterol generation and failure to suppress de novo cholesterol synthesis in macrophages after cholesterol loading with acLDL and correction of these defects after treatment with supplemental LAL. These results extend our previous findings of the impaired ABCA1 expression and cholesterol efflux machinery in fibroblasts of patients with LAL deficiency 7 and indicate a major role for LAL as a regulator of macrophage cholesterol homeostasis and whole-body RCT.
Using immortalized peritoneal macrophages, we found reduced basal and lipoprotein-stimulated ABCA1 and ABCG1 expression and reduced apoA-I-dependent cholesterol efflux in lal −/− compared with lal +/+ macrophages, with partial correction of ABCA1 expression and cholesterol efflux from these cells by addition of rhLAL (Figures 1 through 3) . rhLAL supplementation resulted in normalization of elevated radiolabeled CEs and an increase in free cholesterol in lal −/− macrophages. This correlated directly with correction of production of 27-hydroxycholesterol, produced in mitochondria by sterol-27-hydroxylase and a necessary driver of ABCA1 expression in macrophages via activation of the nuclear receptor LXR on the promoter region of ABCA1, 35 in lal −/− macrophages. These results provide evidence that LAL is critical in regulating both the expression of ABCA1 by generating lysosomally derived cholesterol for 27-hydroxycholesterol production and by providing a substrate for ABCA1-dependent cholesterol efflux from macrophages. We also found an inability of acLDL loading to suppress new cholesterol synthesis in lal −/− macrophages and correction of this defect after addition of rhLAL. These results are consistent with a similar inability of LDL loading to suppress new cholesterol synthesis in LAL-deficient human fibroblasts 29 and further demonstrate the critical role of lysosomally derived cholesterol in regulating downstream cholesterol metabolism in cells.
Further evidence of impaired LXR-dependent gene expression in LAL deficiency is the low level of ABCG5 and ABCG8 mRNA and protein, previously shown to be LXR responsive, 32 seen in lal −/− compared with lal +/+ mouse liver ( Figure 5 ) and as described previously at the mRNA level. 33 We did not find reduced ABCA1 mRNA in lal −/− mouse liver, consistent with a previous report 33 and the known lack of LXR dependence of hepatic ABCA1 expression in mice. 31 Reduced ABCA1 protein was seen in the liver of lal −/− mice, however, possibly because of the high level of Kupffer cells-a type of macrophage-in the liver of these mice 34 or possibly more rapid degradation of ABCA1 protein in the plasma membrane of liver cells in the highly fatty lal −/− mouse liver. The lack of significant reduction of plasma HDL cholesterol in lal −/− mice, 34 however, suggests that hepatic ABCA1-a major determinant of circulating HDL levels 36 -is still functional in these mice.
To determine the role of LAL in promoting whole-body RCT from macrophages to feces, we injected lal +/+ and lal −/− macrophages loaded with acLDL radiolabeled in the cholesterol moiety of CE intraperitoneally into mice of the same genotype. In this method, the injected macrophages have been shown to remain in the peritoneal cavity during the duration of the experiment, 24,37 meaning cholesterol efflux from these cells is dependent on HDL and apoA-I that diffuse into the peritoneal cavity from the circulation, and on LAL produced by the macrophages or other cells in this cavity or diffusing in from the circulation. All mice were injected with equivalent levels of labeled 3H-CE-acLDL in macrophages; based on a 2-fold higher uptake of acLDL by lal −/− compared with lal +/+ macrophages ( Figure 3 ) and an approximate 2-fold higher CE mass in lal −/− macrophages loaded in this way, 38 normalization of injected 3H-CE into the mice provided an equivalent pool of macrophage CE mass available for hydrolysis by LAL, efflux, and movement through the RCT pathway in all mice. These findings have significant implications for the ability of supplemental LAL to correct RCT in humans with LAL deficiency. In addition to the marked reduction of hepatic fat content and liver transaminase levels seen within weeks of initiation of intravenous rhLAL treatment, this treatment significantly raises low HDL cholesterol levels in these individuals. 9 This finding is consistent with hepatic ABCA1-a major predictor of plasma HDL cholesterol levels 36 and an LXR-responsive gene in humans 40, 41 -being corrected by rescue of hepatic LAL activity with this treatment. The ability of circulating LAL to diffuse into the artery wall would also be expected to correct macrophage LAL activity at least partially and along with the increased plasma HDL cholesterol level result in reduced arterial macrophage cholesterol accumulation and plaque burden. Correction of hepatic ABCG5 and ABCG8 expression with this treatment would also enhance RCT in LAL-deficient individuals.
We also found reduced ABCA1 protein levels in the spleen and kidney of lal −/− mice ( Figure III in the online-only Data Supplement). Although these findings may not directly impact the results of our RCT studies, reduced expression of ABCA1 in the spleen has been shown to enhance chemokine production by splenic macrophages, 42 which could contribute to the atherogenic phenotype in LAL deficiency. Reduced renal ABCA1 expression could potentially exacerbate the increased catabolism of apoA1 seen in ABCA1 deficiency. 43 In addition to reduced ABCA1 expression, reduced expression of ABCG1 would also reduce cholesterol efflux by macrophages and would be expected to be corrected with LAL supplementation. ApoE and SR-BI expression were not reduced in lal −/− macrophages, consistent with previous reports of the lack of LXR responsiveness of these genes in human and mouse macrophages. [44] [45] [46] We observed a significant increase in ApoE mRNA expression in lal −/− cells treated with acLDL loading compared with untreated lal +/+ cells, possibly as an LXR-independent compensation to the cholesterol loading. 47 Cholesterol efflux from lal −/− macrophages was nevertheless impaired ( Figure 3A) , consistent with the significantly reduced UC pool available for efflux ( Figure 3C ) and that apoE and SR-B1 are not able to compensate for the reduced activities of ABCA1 and ABCG1 caused by LAL deficiency.
Limitations of this study include the absence of a test of RCT from lal +/+ macrophages injected into lal −/− mice. Although this condition would allow examination of the specific roles of macrophage and hepatic LAL in promoting RCT, it would not represent a relevant therapeutic condition where LAL is deficient in all cells of the body. The amount of LAL secreted by lal +/+ macrophages in the peritoneal cavity would not be expected to have a significant systemic effect, including in the liver, compared with LAL replacement delivered intravenously in humans. 9 We also noted a significant level of residual hydrolysis of acLDL in lal −/− macrophages. This is apparently nonlysosomal because incubation of lal −/− macrophages with chloroquine did not further reduce CE hydrolysis in the cells ( Figure I in the online-only Data Supplement). Despite this finding, this level of hydrolysis did not appreciably affect ABCA1 regulation, further supporting the conclusion that release of lysosomally derived UC is a key regulator of regulatory oxysterol production and ABCA1 expression but not cholesterol derived from nonlysosomal CE hydrolysis.
A recent publication has also found that knockdown of LIPA in macrophages derived from human pluripotent stem cells abolished apoA-I-mediated efflux of cholesterol derived from 3H-CE-acLDL but did not find a relationship between LIPA and expression of ABCA1 in these cells. 11 The reasons for this difference from those in the current studies are not clear. Our results using human fibroblasts, 7 immortalized mouse peritoneal macrophages, and multiple tissues in lal −/− mice are consistent in showing a clear relationship between LAL activity and ABCA1 expression and are also consistent with our previous findings of the critical role of lysosomally derived cholesterol in regulating ABCA1 in Niemann Pick Disease type C. 20, 48 In conclusion, these results implicate LAL as a key regulator of macrophage cholesterol metabolism, including expression of ABCA1 and ABCG1, and an essential driver of whole-body RCT. Our results clearly demonstrate a beneficial role of LAL supplementation in a deficient state for transport of lipoprotein-derived cholesterol in peripheral lipid-loaded macrophages back to the liver for excretion. This suggests that treatment with rhLAL would increase RCT and potentially reduce the elevated risk of premature atherosclerosis in LAL-deficient individuals.
